Regeneron and Sanofi's Dupixent succeeds in late-stage study

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to ...

Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript

Connect Biopharma Holdings Limited ( CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST ...
The Indianapolis Star

Parents of child with rare disease worry after NIH cuts grant that provides him treatment

Charlie Evans, 13, who suffers from severe food allergies and eosinophilic esophagitis (EoE), takes part in an NIH-funded study at Cincinnati Children's hospital. The NIH dismissed the hospital's ...